Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1 to 29-year-olds in Burkina Faso in 2010. The authors of this article, published in Clinical Infectious Diseases, conducted a post-vaccination repeated cross-sectional meningococcal carriage study in a representative portion of the 1 to 29-year-old population in three districts in Burkina Faso. They found that NmA carriage was eliminated in both the vaccinated and unvaccinated population from 3 weeks up to 13 months after mass vaccination. They conclude that the disappearance of NmA carriage among both vaccinated and unvaccinated populations is consistent with a vaccine-induced herd immunity effect. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Kristiansen PA, Diomandé F, Ba AK, et al.
Visit web page (English)
(Located at cid.oxfordjournals.org)
Citation: Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity. Clinical Infectious Diseases. 2013;56(3):354-363.